Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HIV
Biotech
Gilead cancels HIV trial as clinical hold remains intact
After discussions with the FDA, Gilead is discontinuing the Wonders-2 trial comparing the combo of GS-1720 and GS-4182 to Biktarvy.
Darren Incorvaia
Apr 1, 2026 4:50pm
After R&D head exits, Immunocore CEO pairs ambition with caution
Feb 13, 2026 12:44pm
JPM26: Gilead eyes new deals from a 'position of strength'
Jan 14, 2026 3:30am
Study finds HIV can evolve to resist lenacapavir—at a cost
Jan 7, 2026 2:00pm
Addition Tx does the math and emerges from stealth with $100M
Dec 17, 2025 7:45am
Merck's HIV combo matches Gilead's Biktarvy in phase 3 test
Nov 19, 2025 8:10am
